Original Paper

Phylogenetic Analysis of Echovirus 11 in the 3' End of the VP1
Lamjed Bouslama^a, Dorra Rezig^b, Ahlem Ben Yahia^b, Mahjoub Aouni^a, Hinda Triki<sup>b

a</sup>Laboratory of Transmissible Diseases and Biologically Active Substances, Faculty of Pharmacy, Monastir, and
^bLaboratory of Clinical Virology, Pasteur Institute, Tunis, Tunisia

Address of Corresponding Author

Intervirology 2007;50:108-114 (DOI: 10.1159/000098236)

  Key Words

• Enterovirus
• Genogroup
• Lineage
• Antigenic sites

  Abstract

Objective: Echovirus 11 is one of the most frequently isolated enterovirus serotypes, causing a wide range of clinical diseases. We studied the genetic diversity in the 3' end of the VP1 gene of strains from different geographical origin in the world. Methods: The sequences in the 3' end of the VP1 of 11 Tunisian isolates were determined and aligned with the published sequences to establish a phylogenetic profile. Results: The grouping of the sequences was similar to what was previously reported by analyzing the whole VP1 gene with 4 genogroups, designated A-D, and 5 lineages in genogroup D. All Tunisian strains belonged to genogroup D, together with other sequences mainly from the USA and Europe. Contrary to the sequences from the USA isolated during the last 3 decades, which mostly belonged to the D4 lineage, those from Tunisia belonged to different lineages within genogroup D according to their isolation date: isolates from the early 1990s belonged to D3, those of the mid 1990s to D4 and the most recent ones to D5. Conclusion: Our findings further widen the interest of partial sequencing in the VP1 to study the molecular epidemiology of echovirus 11 and indicate that the genetic evolution of circulating strains may differ from one country to another according to the region's epidemiological specificities.

Copyright © 2007 S. Karger AG, Basel

  References

1.

Melnick JL: Enterovirus: poliovirus, coxsackievirus, echoviruses and newer enterovirus; in Fields BN, Knipe DM, Howley PM et al (eds): Fields Virology, ed 3. Philadelphia, Lippincott-Raven, 1996, pp 655-712.

2.

El-Sageyer MM, Szendroi A, Hutter E, Uj M, Szucs G, Mezey I, Toth I, Katai A, Kapiller Z, Pall G, Petras G, Szalay E, Mihaly I, Gourova S, Berencsi G: Characterisation of an echovirus type 11' (prime) epidemic strain causing haemorrhagic syndrome in newborn babies in Hungary. Acta Virol 1998;42:157-166. 

3.

Somekh E, Shohat T, Handsher R, Serour F: An outbreak of echovirus 11 in a children's home. Epidemiol Infect 2001;126:441-444. 

4.

Kennett ML, Donaldson A, Marshall JA, Williamson HG: Echovirus type 11 infection in Melbourne - 1953 to 1980. J Hyg (Lond) 1981;87:305-312. 

5.

Strikas RA, Anderson LJ, Parker RA: Temporal and geographic patterns of isolates of nonpolio enteroviruses in the United States 1970-83. J Infect Dis 1986;153:346-351. 

6.

Druyts-Voets E: Epidemiological features of entero non-poliovirus isolations in Belgium 1980-1994. Epidemiol Infect 1997;119:71-77. 

7.

Atkinson PJ, Sharland M, Maguire H: Predominant enteroviral serotypes causing meningitis. Arch Dis Child 1998;78:373-374. 

8.

Centers for Disease Control and Prevention (CDC): Enterovirus surveillance - United States, 1997-1999. MMWR Morb Mortal Wkly Rep 2000;49:913-916. 

9.

Centers for Disease Control and Prevention (CDC): Enterovirus surveillance - United States, 2000-2001. MMWR Morb Mortal Wkly Rep 2002;51:1047-1049. 

10.

Bahri O, Rezig D, Ben Nejma-Oueslati B, Yahia AB, Sassi JB, Hogga N, Sadraoui A, Triki H: Enteroviruses in Tunisia : virological surveillance over 12 years (1992-2003). J Med Microbiol 2005;54:1-7. 

11.

Oberste MS, Maher K, Kilpatrick DR, Pallansch MA: Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification. J Virol 1999;73:1941-1948. 

12.

Oberste MS, Maher K, Kilpatrick DR, Flemister MR, Brown BA, Pallansch MA: Typing of human enteroviruses by partial sequencing of VP1. J Clin Microbiol 1999;37:1288-1293. 

13.

Oberste MS, Maher K, Flemister MR, Marhetti G, Kilpatrick DR, Pallansch MA: Comparison of classic and molecular approaches for the identification of 'untypable' enteroviruses. J Clin Microbiol 2000;38:1170-1174. 

14.

Caro V, Guillot S, Delpeyroux F, Crainic R: Molecular strategy for 'serotyping' of human enteroviruses. J Gen Virol 2001;82:79-91. 

15.

Norder H, Bjerregaard L, Magnius LO: Homotypic echoviruses share amino-terminal VP1 sequence homology applicable for typing. J Med Virol 2001;63:35-44. 

16.

Oberste MS, Nix WA, Kilpatrick DR, Flemister MR, Pallansch MA: Molecular epidemiology and type-specific detection of echovirus 11 isolates from the Americas, Europe, Africa, Australia, Southern Asia and the Middle East. Virus Res 2003;91:241-248. 

17.

Kapsenberg JG: Picornaviridae: the enteroviruses (polioviruses, coxsackieviruses, echoviruses); in Balows A, et al. (eds): Laboratory Diagnosis of Infectious Diseases. Principles and Practices. Vol. II: Viral, Rickettsial and Chlamydial Diseases.New York: Springer, 1988, pp 692-722.

18.

Chomcznski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159. 

19.

Thompson JD, Higgins DG, Gibson TJ: CLUSTAL W: improving the sensitivity of progressive multiple sequence weighting, position-specific gap penalties and weight-matrix choice. Nucl Acids Res 1994;22:4673-4680. 

20.

Kumar S, Tamura K, Jakobsen B, Nei M: MEGA2: molecular evolutionary analysis software. Bioinformatics 2001;17:1244-1245. 

21.

Seitou N, Nei M: The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987;4:406-425. 

22.

Felsenstein J: Confidence limits on phylogenies: an approach using the bootstrap. Evolution 1985;39:783-791. 

23.

Dahllund L, Nissinen L, Pulli T, Hyttinen VP, Stanway G, Hyypiä T: The genome of echovirus 11. Virus Res 1995;35:215-222. 

24.

Kew OM, Mulders MN, Lipskaya GY, Da Silva EE, Pallansch MA: Molecular epidemiology of poliovirus. Semin Virol 1995;6:401-414. 

25.

Mulders MN, Salminen M, Kalkkinen N, Hovi T: Molecular epidemiology of coxsackievirus B4 and disclosure of the correct VP1/2A (pro) cleavage site: evidence for high genomic diversity and long-term endemicity of distinct genotypes. J Gen Virol 2000;81:803-812. 

26.

Santti J, Harvala H, Kinnunen L, Hyypiä T: Molecular epidemiology and evolution of coxsackievirus A9. J Gen Virol 2000;81:1361-1372. 

27.

Künkel U, Schreier E: Characterization of echovirus 25 in the VP1/2A gene junction region. Arch Virol 1999;144:2253-2258. 

28.

Künkel U, Schreier E: Genetic variability within the VP1 coding region of echovirus type 30 isolates. Arch Virol 2000;145:1455-1464. 

29.

Savolainen C, Hovi T, Mulders MN: Molecular epidemiology of echovirus 30 in Europe: succession of dominant sublineages within a single major genotype. Arch Virol 2001;146:521-537. 

30.

Rico-Hesse R, Pallansch MA, Nottay BK, Kew OM: Geographic distribution of wild type poliovirus type 1 genotypes. Virology 1987;160:311-322. 

31.

Brown BA, Oberste MS, Alexander JP, Kennett ML, Pallansch MA: Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol 1999;73:9969-9975. 

32.

Oberste MS, Maher K, Kennet ML, Campbell JJ, Carpenter MS, Schnurr D, Pallansch MA: Molecular epidemiology and genetic diversity of echovirus type 30: genotypes correlate with temporal dynamics of E30 isolation. J Clin Microbiol 1999;37:3928-3933. 

33.

Rezig D, Ben Yahia A, Ben Abdallah H, Bahri O, Triki H: Molecular characterization of coxsackievirus B5 isolates. J Med Virol 2004;72:268-274. 

34.

Blondel B, Crainic R, Akacem O, Bruneau P, Girard M, Horodniceanu F : Evidence for common, intertypic antigenic determinants on poliovirus capsid polypeptides. Virology 1982;123:461-463. 

35.

Minor PD: Antigenic structure of picornaviruses. Curr Top Microbiol Immunol 1990;161:121-154. 

36.

Mateu MG: Antibody recognition of picornavirus and escape from neutralisation : a structural review. Virus Res 1995;38:1-24. 

37.

Pulli T, Lankinen H, Roivainen M, Hyypia T: Antigenic sites of coxsackievirus A9. Virology 1998,240:202-212. 

38.

Stuart AD, McKee TA, Williams PA, Harley C, Shen S, Stuart DI, Brown DK, Lea SM: Determination of the structure of a decay accelerating factor-binding clinical isolate of echovirus 11 allows mapping of mutants with altered receptor requirements for infection. J Virol 2002;76:7694-7704. 

39.

Chevaliez S, Szendröi A, Caro V, Balanant J, Guillot S, Berencsi G, Delpeyroux F: Molecular comparison of echovirus 11 strains circulating in Europe during an epidemic of multisystem hemorrhagic disease of infants indicates that evolution generally occurs by recombination. Virology 2004,325:56-70. 

  Author Contacts

Lamjed Bouslama
Laboratoire des Maladies Transmissibles et des Substances Biologiquement Actives (LAB-MDT-01), Faculté de Pharmacie
5000, Monastir (Tunisia)
Tel. +216 73 460 000, Fax +216 73 461 830, E-Mail lamjed.bouslama@wanadoo.fr

  Article Information

Received: October 26, 2005
Accepted after revision: February 28, 2006
Published online: December 22, 2006
Number of Print Pages : 7
Number of Figures : 1, Number of Tables : 1, Number of References : 39

  Publication Details

Intervirology (International Journal of Basic and Medical Virology)

Vol. 50, No. 2, Year 2007 (Cover Date: February 2007)

Journal Editor: Liebert, U.G. (Leipzig)
ISSN: 0300-5526 (print), 1423-0100 (Online)

For additional information: http://www.karger.com/INT

  Drug Dosage / Copyright

Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.